4.3 Review

Nutraceuticals in Parkinson's Disease

期刊

NEUROMOLECULAR MEDICINE
卷 18, 期 3, 页码 306-321

出版社

HUMANA PRESS INC
DOI: 10.1007/s12017-016-8398-6

关键词

AMPK; Mitochondria; Parkin; Parkinson's disease; Neurodegeneration

资金

  1. National Medical Research Council-Translational Clinical Research Program in Parkinson's disease
  2. National Medical Research Council-Collaborative Basic Research Grant
  3. National University of Singapore Graduate School for Integrative Sciences and Engineering

向作者/读者索取更多资源

Current pharmacological strategies for Parkinson's disease (PD), the most common neurological movement disorder worldwide, are predominantly symptom relieving and are often plagued with undesirable side effects after prolonged treatment. Despite this, they remain as the mainstay treatment for PD due to the lack of better alternatives. Nutraceuticals are compounds derived from natural food sources that have certain therapeutic value and the advent of which has opened doors to the use of alternative strategies to tackle neurodegenerative diseases such as PD. Notably, nutraceuticals are able to position themselves as a safer'' strategy due to the fact that they are naturally derived compounds, therefore possibly having less side effects. Significant efforts have been put into better comprehending the role of nutraceuticals in PD, and we will look at some of them in this review. Broadly speaking, these compounds execute their positive effects via modulating signalling pathways, inhibiting oxidative stress, inflammation and apoptosis, as well as regulating mitochondrial homoeostasis. Importantly, we will highlight how a component of green tea, epigallocatechin-3-gallate (EGCG), confers neuroprotection in PD via its ability to activate AMP kinase and articulate how its beneficial effects in PD are possibly due to enhancing mitochondrial quality control.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据